ES2962985T3 - Composiciones para el tratamiento del cáncer - Google Patents

Composiciones para el tratamiento del cáncer Download PDF

Info

Publication number
ES2962985T3
ES2962985T3 ES18817894T ES18817894T ES2962985T3 ES 2962985 T3 ES2962985 T3 ES 2962985T3 ES 18817894 T ES18817894 T ES 18817894T ES 18817894 T ES18817894 T ES 18817894T ES 2962985 T3 ES2962985 T3 ES 2962985T3
Authority
ES
Spain
Prior art keywords
elane
cancer
protease
polypeptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18817894T
Other languages
English (en)
Spanish (es)
Inventor
Lev Becker
Chang Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Application granted granted Critical
Publication of ES2962985T3 publication Critical patent/ES2962985T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26003—Ribonuclease III (3.1.26.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
ES18817894T 2017-06-15 2018-06-15 Composiciones para el tratamiento del cáncer Active ES2962985T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520325P 2017-06-15 2017-06-15
US201762610711P 2017-12-27 2017-12-27
PCT/US2018/037800 WO2018232273A1 (en) 2017-06-15 2018-06-15 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
ES2962985T3 true ES2962985T3 (es) 2024-03-22

Family

ID=64659547

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18817894T Active ES2962985T3 (es) 2017-06-15 2018-06-15 Composiciones para el tratamiento del cáncer
ES23191473T Active ES3055526T3 (en) 2017-06-15 2018-06-15 Compositions for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES23191473T Active ES3055526T3 (en) 2017-06-15 2018-06-15 Compositions for treating cancer

Country Status (9)

Country Link
US (1) US12564623B2 (https=)
EP (2) EP4292606B1 (https=)
JP (3) JP7189160B2 (https=)
CN (1) CN111032075A (https=)
AU (1) AU2018285710B2 (https=)
CA (1) CA3066738A1 (https=)
DK (1) DK3638293T5 (https=)
ES (2) ES2962985T3 (https=)
WO (1) WO2018232273A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
CA3184037A1 (en) * 2020-08-18 2022-02-24 Onchilles Pharma, Inc. Modified serine protease proproteins
EP4199947A4 (en) * 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
CN112812150A (zh) * 2021-01-29 2021-05-18 深圳海创生物科技有限公司 一种活性环肽、活性环肽组合物及其在制备具有抗氧化或抗炎作用的产品中的应用
CN113736742B (zh) * 2021-09-08 2023-07-21 河南省医药科学研究院 Prtn3基因作为肿瘤免疫治疗中激活细胞毒性免疫细胞靶点的应用
CN115040642B (zh) * 2022-06-30 2025-03-28 德博尔(成都)生物科技有限公司 一种胰弹性蛋白酶的新用途
CN118443941A (zh) * 2024-04-29 2024-08-06 山东大学齐鲁医院 中性粒细胞作为诊疗膀胱癌的靶标的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA27035C2 (uk) 1990-08-03 2000-02-28 Вертекс Фармас'Ютікалс Інкорпорейтід Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
US5698518A (en) * 1994-03-30 1997-12-16 Oklahoma Medical Research Foundation Method for regulating inflammation and tumor growth with calmodulin, calmodulin analogues or calmodulin antagonists
AU2003231981A1 (en) * 2002-03-29 2003-10-13 Incyte Corporation Protein modification and maintenance molecules
CA2500405A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human myeloid leukemia
JP4408615B2 (ja) 2002-10-07 2010-02-03 独立行政法人科学技術振興機構 好酸球カチオン性タンパク質を含有する組成物
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1649289B1 (en) 2003-07-21 2008-10-22 Roche Diagnostics GmbH Use of proteins proteinase 3 (prn3) and leukocyte elastase inhibitor (ileu) as a marker for colorectal cancer
US7432419B2 (en) * 2004-05-14 2008-10-07 Los Alamos National Security, Llc Compositions and methods for the treatment of Pierce's disease
US20060008891A1 (en) 2004-06-23 2006-01-12 The Government Of Usa As Repersented By The Secretary, Department Of Health And Human Services Cathepsin G-related peptides as modulators of formylpeptide receptors (FPR)
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
WO2010009368A2 (en) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2016125330A1 (ja) 2015-02-02 2016-08-11 原　英彰 網膜再生促進薬

Also Published As

Publication number Publication date
JP7189160B2 (ja) 2022-12-13
EP4292606B1 (en) 2025-11-12
AU2018285710B2 (en) 2025-02-13
EP4292606A3 (en) 2024-02-21
DK3638293T5 (da) 2024-08-26
EP4292606A2 (en) 2023-12-20
EP3638293A4 (en) 2021-03-10
US20210299234A1 (en) 2021-09-30
CN111032075A (zh) 2020-04-17
WO2018232273A1 (en) 2018-12-20
JP2020524141A (ja) 2020-08-13
AU2018285710A1 (en) 2020-01-23
EP3638293A1 (en) 2020-04-22
JP2023022242A (ja) 2023-02-14
ES3055526T3 (en) 2026-02-12
EP3638293B1 (en) 2023-10-04
DK3638293T3 (da) 2023-11-06
CA3066738A1 (en) 2018-12-20
US12564623B2 (en) 2026-03-03
JP7529754B2 (ja) 2024-08-06
JP2024150679A (ja) 2024-10-23

Similar Documents

Publication Publication Date Title
ES2962985T3 (es) Composiciones para el tratamiento del cáncer
ES2653887T3 (es) Procedimiento para aumentar el efecto inmunológico
AU2016350613A1 (en) Conditionally active polypeptides
ES2740953T3 (es) Bloqueo de proteasas inflamatorias con theta-defensinas
JP2026021440A (ja) がん治療のための治療用ペプチドに関する方法および組成物
JP2014506231A (ja) Ｓｍａｄ７の治療的適用
JP6169607B2 (ja) 抗腫瘍アジュバント療法
HK40102823B (en) Compositions for treating cancer
HK40102823A (en) Compositions for treating cancer
US12611443B2 (en) Methods and compositions related to therapeutic peptides for cancer therapy
HK40029045B (en) Compositions for treating cancer
HK40029045A (en) Compositions for treating cancer
Orsolic Possible molecular targets of bee venom in the treatment of cancer: application and perspectives
WO2021243148A2 (en) Methods and compositions for treating alcoholic liver disease
HK40119649A (zh) 与用於癌症疗法的治疗肽相关的方法和组合物
Chriqui Low dose photodynamic therapy promotes vascular E-Selectin expression in malignant pleural mesothelioma which increases immune infiltration and improves tumor control
Wagner Investigation of a Novel Small Molecule TRAIL Inducer, ONC201: Pre-clinical Anti-cancer Efficacy, Anti-metastasis Effects, Tumor Immunity; and the Structure-activity Relationships (SAR) and Mechanism of Action of Potential Analogues
US20150258194A1 (en) Modulating transendothelial migration and recruitment of granulocytes by modulating c-met pathway